AXIM Biotech, Inc. has entered into a clinical study agreement with the renowned University of British Columbia, one of the top three universities in Canada. The study is a clinical trial examining the effectiveness of AXIM’s CBD chewing gum product line as a treatment for psychosis stemming from drug use. This treatment indication is an innovative response to the global drug addiction crisis.
Psychosis is defined by the mental health community as a disconnect between the individual’s perception and reality itself. Psychosis can result in delusions, hallucinations and other distressing experiences for the affected individual. This condition is also known as substance-induced psychotic disorder, and it may be triggered by drug withdrawal, overdose or interactions between drugs, according to the American Addiction Centers.
As explained by the National Alliance on Mental Illness, approximately 3 out of every 100 people experience one or more psychotic episodes in …